Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pharmacists step in to treat bladder infections in women

NCT ID NCT05510128

Symptom relief Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a special protocol used by community pharmacists in France can help women with simple bladder infections (cystitis) get relief more quickly. The goal was to reduce symptoms and avoid unnecessary trips to the doctor or emergency room. The study included 145 women aged 18 to 64 with mild symptoms, but it was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

145 people

The number who actually took part.

Started

Jun 2023

Finished

Jan 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female * Age ≥ 18 and \<65 years * Patient with less than 3 days of simple urinary tract infection symptoms: * Burning, pain on urination * Dysuria * Pollakiuria * Urinary urgency * Patient affiliated or beneficiary of a social insurance * Patient having signed an informed consent. Exclusion Criteria: * More than 3 cystitis in the last 12 months; * Last cystitis less than 15 days old; * Presence of fever; * Presence of back pain; * Presence of a functional or organic anomaly of the urinary tract (bladder residue, vesico-ureteral reflux, lithiasis, tumor); * Pruritus or vaginal discharge; * Vomiting, diarrhea, diffuse abdominal pain; * Risk factors for C3G-resistant enterobacteria infection (grade B): * Exposure to an antibiotic (amoxicillin-clavulanic acid, C2G, C3G, fluoroquinolones) within the previous 3 months; * A nosocomial or healthcare-associated infection; * A history of colonization or infection with C3G-resistant enterobacteria within the last 3 months; * A trip to a foreign country within the last 3 months in known geographical areas at risk (in particular the Indian subcontinent, South-East Asia, the Middle East and North Africa, the Mediterranean basin); * Hospitalization within 3 months; * Hospitalization within 6 months for UTI; * Known severe renal insufficiency (creatinine clearance \< 30 mL/min); * Severe immunosuppression or immunosuppressive treatments; * Contraindications to drugs planned for experimental management (pivmecillinam and fosfomycin) or combination of drugs not recommended; * Pregnant women (confirmed or suspected pregnancy), breastfeeding women or women in labour; * Person deprived of liberty by judicial or administrative decision; * Person under forced psychiatric care; * Person admitted to a health or social institution for purposes other than research; * Person subject to a legal protection measure; * A person who is unable to give consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cystitis acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute cystitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cystitis acute

Contacts and locations

Locations

  • Pharmacie Degueille

    Chemazé, France

  • Pharmacie Deroche

    Roézé-sur-Sarthe, France

  • Pharmacie Llacuna

    Sainte-Anne-sur-Brivet, France

  • Pharmacie Nicolleau-Dilé

    Chemillé-Melay, 49120, France

  • Pharmacie de Brûlon

    Brûlon, France

  • Pharmacie de la Place

    La Ferté-Bernard, France

  • Pharmacie de la Pointe

    Le Mans, France

  • Pharmacie de la Source

    Sougé-le-Ganelon, France

  • Pharmacie des Arcades

    Nozay, France

  • Pharmacie des Halles

    Craon, France

  • Pharmacie du Centre

    Le May-sur-Èvre, France

  • Pharmacie du Chemin Vert

    Saumur, France

  • Pharmacie du Louet

    Mûrs-Erigné, France

  • Pharmacie du Pays De Retz

    Bourgneuf-en-Retz, 44580, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.